放线菌R2A14A-1的活性代谢产物分离及菌株鉴定

Identification of strain R2A14A-1 and its bioactive secondary metabolite

目的抗金黄色葡萄球菌化合物FFF-13的分离鉴定及其塔克拉玛干沙漠南麓来源产生菌R2A14A-1的初步鉴别。方法以琼脂平板扩散法和化合物紫外特征追踪R2A14A-1发酵液中抗金黄色葡萄球菌的amicoumacin类化合物,通过大孔吸附树脂和高效液相等色谱法建立空白培养基与菌株发酵液比对指纹图谱,通过比对分离获得活性次级代谢产物FFF-13,根据高分辨质谱、核磁共振氢谱和碳谱数据并结合文献确定化合物FFF-13的结构;综合菌株R2A14A-1的形态特征、培养特征、生理生化特性和16S rRNA基因序列分析对菌株R2A14A-1进行初步鉴定。结果化合物FFF-13为amicoumacin B,菌株R2A14A-1为拟诺卡菌属放线菌。结论菌株R2A14A-1为首个发现产生amicoumacin类抗生素的拟诺卡菌株。

Objective Isolation and structural identification of secondary metabolite FFF-13 with anti- Staphylococcus aureus from the culture broth of strain R2A14A-1 isolated from the south edge of the Taklamakan Desert in Xinjiang province in China, and preliminary identification of its producing strain R2A14A-1. Methods Based on paper disc diffusion assay and UV spectra, HPLC fingerprint was established to identify the secondary metabolites by comparison of the fermentation broth with the blank culture medium after macroporous resin absorption and acetone water solution elution. Compound FFF-13 was identified as an active secondary metabolite and finally purified by HPLC. The chemical structure of FFF-13 was determined by HR-ESI-MS, NMR analysis and data comparisons with that of the related literature. Preliminary identification of strain R2A14A-1 was carried out by the method of comprehensive analysis of its phylogenetic relationships, combined with morphological, cultural and physiological characteristics. Results Compound FFF-13 was identified as amicoumacin B and the strain R2A14A-1 was affiliated with the genus Nocardiopsis. Conclusion To our best knowledge, it is the firstly reported that a Nocardiopsis strain can produce amicoumacin group antibiotics.